Sherene Loi
Impact in
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Cancer Research top 0.02%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 337
- Cancer Immunotherapy and Biomarkers 148
- HER2/EGFR in Cancer Research 134
- Cancer Treatment and Pharmacology 71
- Cancer Cells and Metastasis 31
- Cancer Research 160
- Breast Cancer Treatment Studies 111
- Cancer Genomics and Diagnostics 65
- Co-authors
- Christos SotiriouMartine PiccartHiroji IwataRoberto SalgadoSeock‐Ah ImHope S. RugoPeter SavasStefan Michiels
- Journals
- Journal of Clinical Oncology (81 papers)Cancer Research (77 papers)Annals of Oncology (69 papers)JNCI Journal of the National Cancer Institute (12 papers)The Breast (12 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Sherene Loi
428 papers receiving 34.4k citations
Hit Papers
Peers
Comparison fields: 5 of 158
- Oncology 24.0k
- Cancer Research 11.0k
- Immunology 7.5k
- Pulmonary and Respiratory Medicine 10.9k
- Genetics 2.0k
Countries citing papers authored by Sherene Loi
This map shows the geographic impact of Sherene Loi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherene Loi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherene Loi more than expected).
Fields of papers citing papers by Sherene Loi
This network shows the impact of papers produced by Sherene Loi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherene Loi. The network helps show where Sherene Loi may publish in the future.
Co-authors
The 25 scholars most cited alongside Sherene Loi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 7 | |
| 5 | 2023 | 9 | |
| 6 | 2023 | 2 | |
| 7 | 2022 | 64 | |
| 8 | 2020 | 51 | |
| 9 | Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade Hit paper breakdown → | 2019 | 412 |
| 10 | 2018 | 51 | |
| 11 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial Hit paper breakdown → | 2018 | 401 |
| 12 | 2017 | 60 | |
| 13 | 2017 | 63 | |
| 14 | 2017 | 148 | |
| 15 | 2017 | 55 | |
| 16 | 2016 | 142 | |
| 17 | 2015 | 270 | |
| 18 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 Hit paper breakdown → | 2013 | 1213 |
| 19 | 2012 | 278 | |
| 20 | 2011 | 256 |
About Sherene Loi
Sherene Loi is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 442 papers that have together received 34.8k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (177 papers), Cancer Immunotherapy and Biomarkers (148 papers), HER2/EGFR in Cancer Research (134 papers), Breast Cancer Treatment Studies (111 papers), Cancer Treatment and Pharmacology (71 papers), Cancer Genomics and Diagnostics (65 papers), Immunotherapy and Immune Responses (35 papers) and Cancer Cells and Metastasis (31 papers). The work is most often cited by research in Oncology (24.0k citations), Cancer Research (11.0k citations), Immunology (7.5k citations), Pulmonary and Respiratory Medicine (10.9k citations) and Genetics (2.0k citations). Sherene Loi has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Christos Sotiriou, Martine Piccart, Hiroji Iwata, Roberto Salgado, Seock‐Ah Im, Hope S. Rugo, Peter Savas, Stefan Michiels, Fabrice André and Peter Schmid. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, JNCI Journal of the National Cancer Institute and The Breast.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.